It’s not often that a small drug company convinces Wall Street’s big banks that its stock could double.
Nuvation Bio (NUVB) just got that call.
On Tuesday, Aug. 18, 2026, JPMorgan started covering the stock with an Overweight rating, which is the firm’s way of saying it expects the shares to beat the market.
The bank set a price target of $13, roughly double where the stock recently traded.
A price target is an analyst’s estimate of where a stock could go over a set period, and JPMorgan’s target runs through Dec. 2027. So this is a long-term call, not a quick trade.
The reason for the bank’s optimism is a product that reached the market this year.
Here is what the call means for investors — and where the risks are.
What is behind JPMorgan’s 100% upside call on Nuvation Bio
JPMorgan’s confidence rests mostly on IBTROZI, a lung cancer pill that Nuvation launched earlier in 2026.
The drug treats a specific group of non-small cell lung cancer patients whose tumors carry a change in a gene called ROS1. It works as a targeted therapy, meaning it goes after that specific genetic driver instead of attacking cells broadly the way older chemotherapy does.
Related: UBS strongly resets Lilly stock target
IBTROZI reached the market at a good moment for the company. In the first half of 2026, it became the most prescribed ROS1 targeted therapy for both new patients and first-time treatments, according to Investing.com.
That early lead matters because it shows doctors are choosing the drug quickly, which is the clearest sign a new medicine can grow into steady revenue.
How IBTROZI’s fast start showed up in Nuvation’s earnings
The strong sales are no longer a projection. It appeared in the company’s most recent quarter.
On Aug. 6, 2026, Nuvation reported second-quarter revenue of $31.7 million, ahead of the roughly $27 million analysts expected, according to a press release. Net product sales from IBTROZI made up $23.2 million of that total.
More Healthcare Stocks:
- BofA biotech scorecard: Two buys and odd one out
- BofA stays bullish on Gilead after a strong HIV signal
- J&J’s biotech progress could punish its 2027 profit
The company still lost money, though. Adjusted loss came in at 18 cents a share, three cents worse than expected, as Investing.com noted. That gap between rising sales and continued losses is normal for a young drug company.
Nuvation is spending heavily to build its sales force and push more drugs through testing, which eats into profit today in exchange for a shot at bigger revenue later.
The revenue side of the story is working faster than expected, even as profits stay negative for now.
The second drug that could widen Nuvation’s opportunity
IBTROZI is not the only reason JPMorgan likes the stock. The bank also pointed to safusidenib, an experimental drug for a type of brain tumor called IDH1-mutant glioma.
JPMorgan sees strong sales potential if the drug clears its remaining studies.
Safusidenib is still in testing, so it carries no revenue yet. The key data that will show whether it works, called progression-free survival readouts, are still years away.
That timeline is worth remembering. One drug, IBTROZI, is already selling, while the second is years away from proving itself.
A stock with one commercial product and one promising candidate can move sharply in either direction on trial news.
Why the stock looks cheap compared with its own history
Part of JPMorgan’s argument is that Nuvation trades well below its past valuation.
The stock’s price-to-sales ratio, which compares its market value to its yearly revenue, sits near 14.8.
JPMorgan sees room for the shares to rise if sales keep climbing, since the ratio is still low for a commercial-stage cancer drug maker.
A low price-to-sales figure alone does not make a stock a bargain. It only helps if the company keeps growing revenue, which is exactly the bet here.
Nuvation’s stock has actually fallen about 18% since the start of 2026, closing near $6.48 before JPMorgan’s call. Over the past five trading days, though, the shares gained about 8%.
That mix of a weak year and a recent bounce is the setup JPMorgan is stepping into.
The risks every Nuvation investor should weigh first
The upside case comes with real dangers, and they deserve equal attention.
Small biotech companies that depend on one or two drugs can lose most of their value if sales slow or a trial fails. Nuvation fits that profile.
A few specific risk factors stand out:
Key risks for Nuvation Bio investors
- The stock carries a beta of 1.52, meaning it tends to move about 52% more than the overall market, according to MarketBeat.
- The stock has traded as high as $9.75 over the past year, showing how wide the swings can be.
- The company posts a negative net margin near 88% and a negative return on equity around 47%, so standard profit measures do not yet apply.
- Insiders have been net sellers of the stock in recent months, a cautious signal from the people who know the company best.
To fund its spending, Nuvation raised $250 million through a 0.75% convertible notes offering in June 2026.
The amount grew to $287.5 million once underwriters fully exercised the over-allotment option.
The company also has a pending $30 million milestone payment tied to European IBTROZI approval, expected in the first half of 2027, from partner Eisai.
That cash gives the company room to operate, but it also shows how much money a biotech burns before it turns a profit.
Where the rest of Wall Street stands on Nuvation Bio
JPMorgan is bullish, but it is not standing alone, and it is not the most aggressive voice either.
Nuvation holds a Strong Buy consensus rating. All eight analysts covering the stock rate it a Buy, with an average price target of $14.86.
That average is above JPMorgan’s call, which means that even among believers, opinions on how far the stock can run vary a great deal.
What Nuvation still needs to prove
A 100% gain is a target, not a promise, and several things must go right first.
IBTROZI needs to keep taking market share, not just win early adopters.
The company’s next earnings report, expected around Nov. 2, 2026, will show whether the sales momentum held through the third quarter.
Safusidenib needs clean trial data before it can add meaningful revenue, and that answer is years out.
For investors, the practical approach is to treat Nuvation as a higher-risk position rather than a core holding. The reward could be large, but so could the loss if a single drug stumbles.
Watch the November earnings report and the drug’s prescription trends to see whether the target is realizable.
Related: Goldman Sachs sees writing on the wall for Eli Lilly stock
